

# Subject Index 2011

- <sup>131</sup>I radionuclide: 2/143-146  
<sup>18</sup>F-choline PET/CT: 1/17-21  
 adaptive planning: 3/220-226  
 adenoma: 2/129-131  
 anaemia: 2/129-131  
 apoptosis: 2/116-122; 3/196-203  
 apparent diffusion coefficient: 2/97-101  
 applications, safety: 4/227-247  
  
 backward wave: 2/82-90  
 biopsy: 1/22-26  
 body contour: 3/184-188  
 body outlining: 3/184-188  
 bone morphogenetic protein 4: 4/259-266  
 bone reconstruction: 4/304-309  
 BRAF: 4/285-291  
 brain: 4/304-309  
 breast cancer: 2/116-122; 3/166-173; 3/184-188; 4/296-299  
 Brunner's gland: 2/129-131  
  
 cancer: 4/259-266  
 cancer therapy: 1/1-16  
 carcinoma: 4/300-303  
 cathepsin H: 4/259-266  
 CD133/prominin1: 2/102-115  
 central venous catheterization: 1/27-30  
 cerebrospinal leak: 2/91-96  
 chemotherapy: 2/75-81; 2/116-122; 4/273-278  
 children: 4/248-258  
 colorectal cancer: 2/75-81  
 compensators: 4/310-314  
 computed tomography: 3/180-183  
 computed tomography dose index: 1/64-67  
  
 cone-beam computerized tomography, kV CBCT: 3/220-226  
 conformal radiotherapy: 3/213-219  
 Croatian Medical Association, Croatian Society of Radiology: 2/147-158  
 CT: 2/91-96  
 CT to density table: 3/220-226  
 CT, MR imaging, diffusion weighted imaging: 1/22-26  
 cutaneous metastases: 4/292-295  
 cysteine cathepsins: 2/102-115  
  
 delivery systems: 1/1-16  
 desmoid tumour: 1/59-63  
 diagnosis: 1/17-21; 2/91-96  
 differential diagnosis: 1/59-63  
 differentiated thyroid cancer: 3/189-195  
 dose profile: 1/64-67  
 dosimetry: 2/132-142; 4/310-314  
  
 echocardiography: 3/180-183  
 effective circulating blood volume: 2/82-90  
 elastic recoil: 2/82-90  
 electrodes: 3/204-208  
 electrogene therapy: 1/30-39  
 electron density phantom: 3/220-226  
 electronic portal imaging device: 1/68-74  
 electroporation: 1/30-39  
 electrotransfection: 1/30-39  
 ependymoma: 2/97-101  
  
 fluorescence-guided resection: 3/159-165  
 follow-up: 1/17-21  
 functional analysis: 4/248-258  
  
 Gafchromic film: 1/64-67  
 gamma knife: 2/132-142  
 gastrointestinal stromal tumour: 1/59-63  
 gene electrotransfer: 3/204-208  
 gene screening: 4/296-299  
 GIST: 1/59-63  
 glioblastoma: 2/102-115  
 glioblastoma multiforme: 3/213-219  
 glioma stem cells: 2/102-115  
  
 head and neck cancer: 1/40-45  
 healthy blood donors: 3/209-212  
 helical computed tomography: 1/27-30  
 hemangiopericytoma: 1/22-26  
 hepatocellular carcinoma: 4/292-295  
 history: 2/147-158  
 human cell lines: 4/259-266  
 human papillomavirus infection: 4/267-272  
  
 IL-12: 1/30-39  
 image cytometry: 1/40-45  
 image-guided surgery: 3/159-165  
 immunohistochemistry: 4/279-284  
 INF- $\gamma$ : 1/30-39  
 intradermal injection: 3/184-188  
 invasion: 2/102-115; 4/304-309  
 inverted papilloma: 4/267-272  
  
 KRAS: 4/285-291  
  
 laparoscopy: 4/273-278  
 left ventricular pseudoaneurysm: 3/180-183  
 low iodine diet: 3/189-195

- lymphoma, non-Hodgkin: 1/27-30  
 lymphoscintigraphy: 3/184-188  
  
 M30: 2/116-122  
 magnetic nanoparticles: 1/1-16  
 magnetic resonance  
   cholangiography: 4/300-303  
 magnetic resonance imaging:  
   4/300-303  
 magnetic targeting: 1/1-16  
 magnetofection: 1/1-16  
 male: 4/296-299  
 malignant glioma: 3/159-165  
 mast cell tumors: 1/30-39  
 MCNPX code: 2/143-146  
 meningioma: 4/304-309  
 mesenteric fibromatosis: 1/59-63  
 metastatic colorectal cancer:  
   4/285-291  
 metastatic tumours: 1/53-58  
 microsatellite instability: 2/75-81  
 MR urography: 3/174-179;  
   4/248-258  
 MRI: 2/91-96  
 multidetector computed  
   tomography: 4/300-303  
 multiple basilar skull fracture:  
   2/91-96  
 multislice CT: 1/64-67  
  
 nanoparticles: 4/227-247  
 nanotechnology: 1/1-16  
 neural stem cells: 2/102-115  
 neuronavigation: 3/159-165  
 NF- $\kappa$ B, serine-536: 4/279-284  
 nuclear features: 1/40-45  
  
 oncology: 1/1-16  
 outcome: 4/267-272  
 ovarian cancer: 3/196-203  
  
 paediatrics: 3/174-179  
 pancreatic cysts: 4/300-303  
 pancreatic intraepithelial  
   neoplasia: 4/300-303  
 pelvis: 1/22-26  
 pencil chamber: 1/64-67  
 perfexion: 2/132-142  
 pilocytic astrocytoma: 2/97-101  
 pipette tip, CHO cell line:  
   3/204-208  
 portal film: 1/68-74  
 principal wave: 2/82-90  
 prognosis: 1/40-45; 2/123-128;  
   4/273-278; 4/279-284  
 prognostic factors: 1/46-52;  
   3/213-219; 4/285-291  
 prostate carcinoma: 1/17-21  
 proteolytic enzymes: 4/259-266  
  
 quality control: 1/68-74  
  
 radiation therapy: 4/310-314;  
   4/292-295  
 radioiodine: 3/189-195  
 radiological contrast: 3/166-173  
 radiology: 2/147-158  
 radiotherapy: 1/22-26; 4/267-272;  
   4/279-284  
 rectal cancer: 3/209-212  
 rectal cancer: 4/279-284  
 recurrence: 4/279-284  
 resistance: 2/82-90  
 response to chemotherapy:  
   2/116-122  
 RNA interference: 3/196-203  
 ROLL technique: 3/166-173  
  
 scattered photons: 3/184-188  
 secondary malignancies: 1/53-58  
 secondary neoplasm: 4/296-299  
 shutter effect: 2/132-142  
  
 SKOV3 cells: 3/196-203  
 squamous cell carcinoma:  
   4/267-272  
 stage II colon cancer: 4/273-278  
 staging: 1/17-21  
 stat3: 3/196-203  
 stereotactic radiosurgery:  
   2/132-142  
 surgery: 3/159-165; 3/166-173  
  
 targeted chemotherapy:  
   2/123-128  
 temozolomide: 3/213-219  
 thyroid gland: 2/143-146  
 thyroid malignancy: 1/53-58  
 TIMP-1: 3/209-212  
 titanium dioxide: 4/227-247  
 total energy deposition:  
   2/143-146  
 toxicity: 4/227-247  
 transcranial magnetic  
   stimulation: 3/159-165  
 treatment outcome: 1/46-52  
 triple negative breast cancer:  
   1/46-52  
 triple-negative breast cancer:  
   2/123-128  
  
 urinary tract: 3/174-179;  
   4/248-258  
 urine iodine concentration:  
   3/189-195  
  
 velocity tracing: 2/82-90